Kymera Therapeutics (NASDAQ:KYMR) Shares Down 6.7% - Here's What Happened

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report)'s share price fell 6.7% during mid-day trading on Friday . The company traded as low as $42.86 and last traded at $42.86. 150,856 shares traded hands during trading, a decline of 74% from the average session volume of 586,785 shares. The stock had previously closed at $45.94.

Analysts Set New Price Targets

KYMR has been the subject of a number of recent analyst reports. Morgan Stanley increased their price target on Kymera Therapeutics from $45.00 to $49.00 and gave the company an "equal weight" rating in a research report on Wednesday, November 6th. Leerink Partnrs upgraded shares of Kymera Therapeutics to a "strong-buy" rating in a research report on Monday, September 9th. Guggenheim lifted their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a research report on Friday, November 1st. Wells Fargo & Company increased their target price on Kymera Therapeutics from $30.00 to $38.00 and gave the company an "equal weight" rating in a report on Monday, August 12th. Finally, Oppenheimer lifted their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the company an "outperform" rating in a report on Friday, September 27th. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $51.21.

Kymera Therapeutics Trading Down 5.3 %

The stock has a fifty day moving average price of $47.24 and a 200 day moving average price of $41.57. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of -18.47 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.01. The firm had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business's quarterly revenue was down 20.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.90) EPS. On average, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other news, Director Jeffrey W. Albers sold 5,000 shares of the firm's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Pamela Esposito sold 13,500 shares of the company's stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. Insiders own 15.82% of the company's stock.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds have recently modified their holdings of the stock. Values First Advisors Inc. bought a new position in shares of Kymera Therapeutics during the third quarter valued at $61,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock valued at $114,000 after buying an additional 504 shares in the last quarter. Comerica Bank boosted its position in Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company's stock valued at $134,000 after buying an additional 400 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new stake in Kymera Therapeutics during the second quarter worth about $139,000. Finally, Quest Partners LLC increased its holdings in shares of Kymera Therapeutics by 1,402.0% during the second quarter. Quest Partners LLC now owns 5,212 shares of the company's stock worth $156,000 after buying an additional 4,865 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.